Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | FPR3 | P25089 | 1/20 | 0.43 |
| ▸ | FPR2 | P25090 | 1/20 | 0.43 |
| ▸ | PDE8B | O95263 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 2/20 | 0.42 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.42 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL539034 | 1.00 | HSD17B10 (0.48) | HSD17B10SMN1; SMN2ALDH1A1FPR3FPR2 | |
| SCHEMBL398772 | 1.00 | HSD17B10 (0.48) | HSD17B10SMN1; SMN2ALDH1A1FPR3FPR2 | |
| SCHEMBL190190 | 0.95 | PDE8B (0.47) | HSD17B10SMN1; SMN2ALDH1A1FPR3FPR2 | |
| SCHEMBL31114914 | 0.90 | HSD17B10 (0.40) | HSD17B10SMN1; SMN2ALDH1A1ATMHPGD | |
| SCHEMBL19950330 | 0.90 | HSD17B10 (0.40) | HSD17B10SMN1; SMN2ALDH1A1ATMHPGD | |
| SCHEMBL19951601 | 0.90 | HSD17B10 (0.40) | HSD17B10SMN1; SMN2ALDH1A1ATMHPGD | |
| SCHEMBL14934749 | 0.88 | HSD17B10 (0.46) | HSD17B10SMN1; SMN2ALDH1A1FPR3FPR2 | |
| SCHEMBL841886 | 0.88 | HSD17B10 (0.46) | HSD17B10SMN1; SMN2ALDH1A1FPR3FPR2 | |
| SCHEMBL33526612 | 0.88 | HSD17B10 (0.46) | HSD17B10SMN1; SMN2ALDH1A1FPR3FPR2 | |
| SCHEMBL47049 | 0.85 | L3MBTL1 (0.58) | HSD17B10SMN1; SMN2ALDH1A1PDE8BNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020030925-A1 | HETEROCYCLIC SUBSTITUTED UREAS, FOR USE AGAINST CANCER | ARTIOS PHARMA LIMITED (GB) | 2020-02-13 | — | — | WO | disclosed |
| US-20130231373-A1 | HYDROXAMATE-BASED INHIBITORS OF DEACETYLASES | NOVARTIS AG (CH) | 2013-09-05 | — | — | US | disclosed |
| US-20130231373-A1 | HYDROXAMATE-BASED INHIBITORS OF DEACETYLASES | NOVARTIS AG (CH) | 2013-09-05 | — | — | US | disclosed |
| US-8268868-B2 | 5-pyridinone substituted indazoles | ALBANY MOLECULAR RESEARCH, INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-8268868-B2 | 5-pyridinone substituted indazoles | ALBANY MOLECULAR RESEARCH, INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-8268868-B2 | 5-pyridinone substituted indazoles | ALBANY MOLECULAR RESEARCH, INC. (US) | 2012-09-18 | — | — | US | disclosed |
| WO-2012025164-A1 | HYDROXAMATE-BASED INHIBITORS OF DEACETYLASES | NOVARTIS AG (CH) | 2012-03-01 | — | — | WO | disclosed |
| US-20110060009-A1 | Hydroxamate-Based Inhibitors of Deacetylases | NOVARTIS AG | 2011-03-10 | — | — | US | disclosed |
| US-20110060009-A1 | Hydroxamate-Based Inhibitors of Deacetylases | NOVARTIS AG | 2011-03-10 | — | — | US | disclosed |
| US-20100105679-A1 | 5-PYRIDINONE SUBSTITUTED INDAZOLES | ALBANY MOLECULAR RESEARCH, INC. (US) | 2010-04-29 | — | — | US | disclosed |
| US-20100105679-A1 | 5-PYRIDINONE SUBSTITUTED INDAZOLES | ALBANY MOLECULAR RESEARCH, INC. (US) | 2010-04-29 | — | — | US | disclosed |
| US-20100105679-A1 | 5-PYRIDINONE SUBSTITUTED INDAZOLES | ALBANY MOLECULAR RESEARCH, INC. (US) | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130231373-A1 | HYDROXAMATE-BASED INHIBITORS OF DEACETYLASES | HDAC1, HDAC11, HDAC3 | HSD17B10 143/4885SMN1; SMN2 2867/4885ALDH1A1 137/4885 |
| US-20100105679-A1 | 5-PYRIDINONE SUBSTITUTED INDAZOLES | CYP3A5, PDXK, PNPO | HSD17B10 1988/4885SMN1; SMN2 196/4885ALDH1A1 273/4885 |
| US-20110060009-A1 | Hydroxamate-Based Inhibitors of Deacetylases | HDAC1, HDAC11, HDAC3 | HSD17B10 155/4885SMN1; SMN2 2787/4885ALDH1A1 137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.